Envoy Medical (COCH) Fundamental Analysis: Revenue, Earnings & Valuation

0.77 / 10

Underperform

Fundamental analysis rates COCH as Underperform with a 0.77/10 score. Profit‑MV and Revenue‑MV show slight strength, but Cash‑MV, ROA and profitability margins are poor, leading to a guarded outlook.

Analysis Checks(2/10)

Revenue-MV

Value-3.94

Score2/3

Weight-4.84%

1M Return1.21%

ROA (%)

Value-236.43

Score0/3

Weight16.84%

1M Return-6.58%

Net cash flow from operating activities / Operating revenue (%)

Value-7552.28

Score0/3

Weight16.88%

1M Return-6.63%

Profit-MV

Value0.66

Score2/3

Weight-14.40%

1M Return3.09%

Annualized net profit margin on total assets (%)

Value-236.43

Score0/3

Weight16.84%

1M Return-6.58%

EBIT / Total operating revenue (%)

Value-9197.51

Score0/3

Weight16.88%

1M Return-5.19%

Asset-MV

Value-0.55

Score0/3

Weight12.53%

1M Return-3.44%

Net profit / Total operating revenue (%)

Value-9857.26

Score0/3

Weight17.19%

1M Return-6.68%

Cash-MV

Value0.02

Score1/3

Weight13.65%

1M Return-4.16%

Net profit / Total profit (%)

Value100.00

Score1/3

Weight8.43%

1M Return-2.39%

Is COCH undervalued or overvalued?

COCH scores 0.77/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -9857.26% net margin, -1.89 P/E ratio, -4.61 P/B ratio, and 17.45% earnings growth, these metrics solidify its Underperform investment rating.